

CLINICAL RESEARCH

Alterations in Titin Properties and Myocardial Fibrosis Correlate With Clinical Phenotypes in Hemodynamic Subgroups of Severe Aortic Stenosis



Michael Gotzmann, MD,^a Susanne Grabbe,^b Dominik Schöne,^b Marion von Frieling-Salewsky,^c Cristobal G. dos Remedios, PhD,^d Justus Strauch, MD,^e Matthias Bechtel, MD,^e Johannes W. Dietrich, MD,^f Andrea Tannapfel, MD, PhD,^g Andreas Mügge, MD,^b Wolfgang A. Linke, PhD^c

JACC: BASIC TO TRANSLATIONAL SCIENCE CME/MOC

This article has been selected as the month's *JACC: Basic to Translational Science* CME/MOC activity, available online at <http://www.acc.org/jacc-journals-cme> by selecting the *JACC Journals CME/MOC* tab.

Accreditation and Designation Statement

The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ACCF designates this journal-based CME/MOC activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Method of Participation and Receipt of CME/MOC Certificate

To obtain credit for *JACC: Basic to Translational Science* CME/MOC, you must:

1. Be an ACC member or *JACC: Basic to Translational Science* subscriber.
2. Carefully read the CME/MOC-designated article available online and in this issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions provided must be answered correctly to obtain CME/MOC credit.
4. Complete a brief evaluation.
5. Claim your CME/MOC credit and receive your certificate electronically by following the instructions given at the conclusion of the activity.

CME/MOC Objective for This Article: Upon completion of this paper, the reader should be able to: 1) understand the different patterns of myocardial fibrosis and the degree of isoform-expression and phosphorylation changes in cardiomyocyte titin in the different hemodynamic subgroups of aortic stenosis; 2) examine the extent of myocardial remodeling in paradoxical aortic stenosis to help better understand the poor prognosis of

these patients; and 3) review the current guidelines and management of severe aortic stenosis, including evaluation focused on hemodynamic subtypes.

CME/MOC Editor Disclosure: CME/MOC Editor L. Kristin Newby, MD, is supported by research grants from Amylin, Bristol-Myers Squibb Company, GlaxoSmithKline, Sanofi-Aventis, Verily Life Sciences (formerly Google Life Sciences), the MURDOCK Study, NIH, and PCORI; receives consultant fees/honoraria from BioKier, DemeRx, Medscape/TheHeart.org, Metanomics, Philips Healthcare, Roche Diagnostics, CMAA Health Education & Research Institute; serves as an Officer, Director, Trustee, or other Fiduciary Role for AstraZeneca HealthCare Foundation and the Society of Chest Pain Centers (now part of ACC); and serves in another role for the American Heart Association and is the Deputy Editor of *JACC: Basic to Translational Science*.

Author Disclosures: This work was supported by the German Heart Foundation/German Foundation of Heart Research. Dr. Dietrich has received funding from Sanofi-Henning, Hexal AG, Bristol-Myers Squibb, and Pfizer; and is co-owner of the intellectual property rights for the patent "System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual" (Singapore Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940-5, WIPO number WO/2014/088516). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Medium of Participation: Online (article and quiz).

CME/MOC Term of Approval


Issue Date: June 2018

Expiration Date: May 31, 2019

From the ^aDepartment of Cardiology, Marien Hospital Witten, Ruhr University Bochum, Bochum, Germany; ^bCardiology and Angiology, Bergmannsheil, Ruhr University Bochum, Bochum, Germany; ^cInstitute of Physiology II, University of Münster, Münster, Germany; ^dDepartment of Anatomy & Histology, Bosch Institute, University of Sydney, Sydney, Australia; ^eDepartment of Cardiac and Thoracic Surgery, Bergmannsheil, Ruhr University Bochum, Bochum, Germany; ^fDepartment of Internal Medicine, Bergmannsheil, Ruhr University Bochum, Bochum, Germany; and the ^gInstitute of Pathology, Ruhr University Bochum, Bochum, Germany. This work was supported by the German Heart Foundation/German Foundation of Heart Research. Dr. Dietrich has received funding from Sanofi-Henning, Hexal AG, Bristol-Myers Squibb, and Pfizer; and is co-owner of the intellectual property rights for the patent "System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual" (Singapore

Alterations in Titin Properties and Myocardial Fibrosis Correlate With Clinical Phenotypes in Hemodynamic Subgroups of Severe Aortic Stenosis

Michael Gotzmann, MD,^a Susanne Grabbe,^b Dominik Schöne,^b Marion von Frieling-Salewsky,^c Cristobal G. dos Remedios, PhD,^d Justus Strauch, MD,^e Matthias Bechtel, MD,^e Johannes W. Dietrich, MD,^f Andrea Tannapfel, MD, PhD,^g Andreas Mügge, MD,^b Wolfgang A. Linke, PhD^c



HIGHLIGHTS

- The extent of myocardial fibrosis and the degree of isoform-expression and phosphorylation changes in cardiomyocyte titin were unknown in different hemodynamic subgroups of AS, including "paradoxical" low-flow, low-gradient AS with preserved ejection fraction.
- Hemodynamic subtypes of AS were found to exhibit increased cardiac fibrosis, titin-isoform transition toward more compliant N2BA variants, and both total and site-specific titin (N2Bus) hypophosphorylation compared with donor heart controls.
- A significant shift toward N2BA titin appeared in "paradoxical" AS, whereas alterations in total-titin phosphorylation and cardiac fibrosis were similar in all hemodynamic subtypes of AS, suggesting increased myocardial passive stiffness.
- The unfavorable prognosis of "paradoxical" AS could be explained by the pronounced myocardial remodeling, which is no less severe than in other AS subtypes.

Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940-5, WIPO number WO/2014/088516). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Basic to Translational Science* [author instructions page](#).

Manuscript received September 18, 2017; revised manuscript received February 12, 2018, accepted February 13, 2018.

Download English Version:

<https://daneshyari.com/en/article/8663242>

Download Persian Version:

<https://daneshyari.com/article/8663242>

[Daneshyari.com](https://daneshyari.com)